This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Start With Proven First-line Efficacy1-3
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.3
Overview
Efficacy was maintained in patients whose dose was reduced4
This was a post hoc exploratory analysis. Therefore, the results of this analysis cannot be used to suggest potential increased efficacy in patients whose dose was reduced.4
All patients in the Phase III study received a starting dose of 45 mg QD and efficacy comparisons of patients by their lowest dose on study (30 mg QD, 15 mg QD) are not likely to reflect the efficacy for these patients had they started with 30 mg QD or 15 mg QD.1,4
Adapted from Corral J, et al. Future Oncol. 2019.
Dose reductions occurred in 66% of patients treated with DACOPLICE®.1
In the ITT population
Dose reduction of DACOPLICE® did not compromise OS in the ITT population5
Adapted from Mok TS, et al. Presented at ESMO. 2019.5
Dose reductions occurred in 66% of patients treated with DACOPLICE®.1
In the Asian population
In the Asian population, dose reduction of DACOPLICE® did not compromise the OS5
OS in all patients on DACOPLICE® versus those who had a dose reduction5,*
Adapted from Mok TS, et al. Presented at ESMO. 2019.5
CI, confidence interval; HR, hazard ratio; IRC, independent radiological central; ITT, intention-to-treat; NR, not reached; OS, overall survival; PFS, progression-free survival; QD, once daily.
References:
Please click the Prescribing Information link to view the safety and adverse events information of DACOPLICE®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-DAC-IND-0147 June 2022
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…
DACOPLICE® is a second-generation EGFR TKI
Learn more
First-line use of DACOPLICE® was studied in a Phase III, head-to-head trial with gefitinib
Review efficacy profile
ARCHER 1050 study reported the most common adverse events in patients
Review safety profile
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022